- Mobile platform intended to produce >1,000s of ready-to-use doses at the site of need in under 3 days
- Project leverages GE’s expertise regarding synthetic method for producing industrial amounts of DNA
- GE’s DNA-based approach could be compatible with new, recently approved RNA-based COVID-19 vaccines
NISKAYUNA, NY – March 2, 2021 – Aiming to enable vaccine production on-demand, anywhere in the world in just days, GE Research and a multi-disciplinary t
For media inquiries, please contact:
Todd AlhartDirector, Innovation Communications
GE Aerospace
+1 518 338 5880
[email protected]